T. Rowe Price Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

T. Rowe Price Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Quarter	Market Value	Status	Shares	Shares Change %	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$1.41B	Buy	3,159,870 +242,643	+8%	+$108M	0.16%	124
2025 Q1	$1.41B	Buy	2,917,227 +1,226,527	+73%	+$595M	0.17%	116
2024 Q4	$681M	Sell	1,690,700 -77,310	-4%	-$31.1M	0.08%	222
2024 Q3	$822M	Sell	1,768,010 -443,664	-20%	-$206M	0.09%	193
2024 Q2	$1.04B	Sell	2,211,674 -2,281,748	-51%	-$1.07B	0.12%	156
2024 Q1	$1.88B	Sell	4,493,422 -1,393,990	-24%	-$583M	0.23%	88
2023 Q4	$2.4B	Sell	5,887,412 -962,654	-14%	-$392M	0.32%	61
2023 Q3	$2.38B	Buy	6,850,066 +91,308	+1%	+$31.8M	0.35%	54
2023 Q2	$2.38B	Buy	6,758,758 +168,568	+3%	+$59.3M	0.33%	54
2023 Q1	$2.08B	Buy	6,590,190 +1,892,523	+40%	+$596M	0.31%	66
2022 Q4	$1.36B	Sell	4,697,667 -460,287	-9%	-$133M	0.22%	99
2022 Q3	$1.49B	Buy	5,157,954 +195,271	+4%	+$56.5M	0.24%	81
2022 Q2	$1.4B	Sell	4,962,683 -342,014	-6%	-$96.4M	0.18%	121
2022 Q1	$1.38B	Sell	5,304,697 -116,594	-2%	-$30.4M	0.14%	151
2021 Q4	$1.19B	Sell	5,421,291 -276,956	-5%	-$60.8M	0.11%	185
2021 Q3	$1.03B	Sell	5,698,247 -7,400,245	-56%	-$1.34B	0.1%	215
2021 Q2	$2.64B	Sell	13,098,492 -3,451,384	-21%	-$696M	0.24%	85
2021 Q1	$3.56B	Sell	16,549,876 -3,077,048	-16%	-$661M	0.36%	50
2020 Q4	$4.63B	Sell	19,626,924 -744,000	-4%	-$176M	0.48%	34
2020 Q3	$5.54B	Sell	20,370,924 -827,578	-4%	-$225M	0.64%	25
2020 Q2	$6.15B	Sell	21,198,502 -425,404	-2%	-$123M	0.77%	18
2020 Q1	$5.15B	Sell	21,623,906 -2,901,999	-12%	-$691M	0.81%	18
2019 Q4	$5.37B	Sell	24,525,905 -1,764,208	-7%	-$386M	0.7%	26
2019 Q3	$4.45B	Buy	26,290,113 +1,404,232	+6%	+$238M	0.63%	29
2019 Q2	$4.56B	Sell	24,885,881 -1,260,763	-5%	-$231M	0.64%	27
2019 Q1	$4.81B	Buy	26,146,644 +397,233	+2%	+$73.1M	0.71%	21
2018 Q4	$4.27B	Buy	25,749,411 +682,806	+3%	+$113M	0.72%	22
2018 Q3	$4.83B	Sell	25,066,605 -577,057	-2%	-$111M	0.7%	19
2018 Q2	$4.36B	Sell	25,643,662 -1,925,016	-7%	-$327M	0.67%	24
2018 Q1	$4.49B	Sell	27,568,678 -770,181	-3%	-$126M	0.71%	19
2017 Q4	$4.25B	Buy	28,338,859 +1,860,145	+7%	+$279M	0.69%	19
2017 Q3	$4.03B	Buy	26,478,714 +1,895,502	+8%	+$288M	0.69%	20
2017 Q2	$3.17B	Buy	24,583,212 +1,604,569	+7%	+$207M	0.57%	28
2017 Q1	$2.51B	Buy	22,978,643 +1,118,318	+5%	+$122M	0.47%	40
2016 Q4	$1.61B	Sell	21,860,325 -1,623,063	-7%	-$120M	0.32%	75
2016 Q3	$2.05B	Buy	23,483,388 +235,525	+1%	+$20.5M	0.41%	53
2016 Q2	$2B	Sell	23,247,863 -1,760,630	-7%	-$151M	0.42%	47
2016 Q1	$1.99B	Buy	25,008,493 +6,185,022	+33%	+$492M	0.42%	45
2015 Q4	$2.37B	Buy	18,823,471 +3,832,331	+26%	+$482M	0.5%	40
2015 Q3	$1.56B	Buy	14,991,140 +1,548,208	+12%	+$161M	0.35%	69
2015 Q2	$1.66B	Sell	13,442,932 -73,956	-0.5%	-$9.13M	0.34%	68
2015 Q1	$1.59B	Buy	13,516,888 +226,285	+2%	+$26.7M	0.33%	71
2014 Q4	$1.58B	Sell	13,290,603 -900,159	-6%	-$107M	0.34%	68
2014 Q3	$1.59B	Buy	14,190,762 +323,978	+2%	+$36.4M	0.35%	64
2014 Q2	$1.31B	Buy	13,866,784 +2,041,774	+17%	+$193M	0.28%	88
2014 Q1	$836M	Buy	11,825,010 +2,465,595	+26%	+$174M	0.19%	139
2013 Q4	$695M	Buy	9,359,415 +2,458,995	+36%	+$183M	0.16%	161
2013 Q3	$523M	Buy	6,900,420 +316,258	+5%	+$24M	0.13%	201
2013 Q2	$526M	Buy	+6,584,162	New	+$526M	0.14%	188